Clinical Trial Update: A Study of PT0253 in Participants With KRAS G12D Mutated Advanced Solid Tumors [Phase 1]

View source ↗

Summary

Phase 1 clinical trial evaluating PT0253 in participants with KRAS G12D-mutated advanced solid tumors; study is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Solid Tumors

Drugs mentioned

• PT0253

Snippet

Sponsor: PAQ Therapeutics, Inc. | Conditions: Solid Tumor | Phase 1 | Status: RECRUITING